В. А. Горбунова

13.9k total citations · 4 hit papers
61 papers, 7.2k citations indexed

About

В. А. Горбунова is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, В. А. Горбунова has authored 61 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Pulmonary and Respiratory Medicine, 46 papers in Oncology and 8 papers in Surgery. Recurrent topics in В. А. Горбунова's work include Lung Cancer Treatments and Mutations (23 papers), Colorectal Cancer Treatments and Studies (20 papers) and Gastric Cancer Management and Outcomes (20 papers). В. А. Горбунова is often cited by papers focused on Lung Cancer Treatments and Mutations (23 papers), Colorectal Cancer Treatments and Studies (20 papers) and Gastric Cancer Management and Outcomes (20 papers). В. А. Горбунова collaborates with scholars based in Russia, United States and Germany. В. А. Горбунова's co-authors include Jaafar Bennouna, Tony Mok, Lecia V. Sequist, Wu‐Chou Su, James Chih‐Hsin Yang, Michael Boyer, Mehdi Shahidi, Dan Massey, Ki Hyeong Lee and Vera Hirsh and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

В. А. Горбунова

53 papers receiving 7.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

2013 2.5k citations Lecia V. Sequist, James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

2007 1.7k citations Bernard Escudier, A Płużańska et al. The Lancet profile →
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

2013 621 citations G. Bodoky, Vladimir Moiseyenko et al. profile →
Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial

2010 425 citations Jaffer A. Ajani, W. Rodriguez et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by В. А. Горбунова

Since Specialization

Citations

This map shows the geographic impact of В. А. Горбунова's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by В. А. Горбунова with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites В. А. Горбунова more than expected).

Fields of papers citing papers by В. А. Горбунова

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by В. А. Горбунова. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by В. А. Горбунова. The network helps show where В. А. Горбунова may publish in the future.

Co-authorship network of co-authors of В. А. Горбунова

This figure shows the co-authorship network connecting the top 25 collaborators of В. А. Горбунова. A scholar is included among the top collaborators of В. А. Горбунова based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with В. А. Горбунова. В. А. Горбунова is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	44P Reintroduction of platinum-based chemotherapy ± mitotane for advanced adrenocortical cancer: Single-center retrospective trial	ESMO Open	В. А. Горбунова, Olga Martynova et al.	0
2	Targeted therapy in the treatment of HER-2 positive breast cancer with brain metastases	Russian Journal of Oncology	В. А. Горбунова et al.	0
3	TAGS: A phase III, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer	Annals of Oncology	Hendrik‐Tobias Arkenau, Josep Tabernero et al.	1
4	A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer	Gynecologic Oncology	Rebecca Kristeleit, Ірина Давиденко et al.	78
5	A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer	Annals of Oncology	Jaffer A. Ajani, Mikhail Abramov et al.	37
6	Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer	Clinical Cancer Research	Suresh S. Ramalingam, Normand Blais et al.	65
7	THE COMPARISON OF THE THERAPEUTIC EQUIVALENCE OF OXALIPLATINRONC® (BRANCH “NAUKOPROFI” OF N.N. BLOKHIN RCRC) AND ELOXATIN® (AVENTIS PHARMA LTD, GREAT BRITAIN) IN MFOLFOX6 COMBINATION AS A FIRST LINE OF CHEMOTHERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER	Malignant tumours	В. А. Горбунова, L. V. Manzyuk et al.	1
8	DRUG THERAPY OF BREAST CANCER PATIENTS WITH METASTATIC BRAIN LESIONS.	Malignant tumours	В. А. Горбунова et al.	0
9	Pharmacoeconomic analysis of Giotrif® (afatinib) as first-line treatment of metastatic non-small cell lung cancer with Del19 mutation of epidermal growth factor receptor (EGFR) gene	Malignant tumours	В. А. Горбунова, С. В. Орлов et al.	1
10	STUDY DATA OF KRAS- AND RAS-UNMUTATED (WILD) TYPE OF COLORECTAL CANCER	SHILAP Revista de lepidopterología	В. А. Горбунова	1
11	A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: Results of the Phase II Randomized ABIGAIL Study (BO21015)	Journal of Thoracic Oncology	Tony Mok, В. А. Горбунова et al.	39
12	Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial	Annals of Oncology	Fabrice Barlési, Arnaud Scherpereel et al.	129
13	Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations breakdown →	Journal of Clinical Oncology	Lecia V. Sequist, James Chih‐Hsin Yang et al.	2461
14	Health-Related Quality of Life in Patients with Advanced Nonsquamous Non–Small-Cell Lung Cancer Receiving Bevacizumab or Bevacizumab-Plus-Pemetrexed Maintenance Therapy in AVAPERL (MO22089)	Journal of Thoracic Oncology	Achim Rittmeyer, В. А. Горбунова et al.	23
15	Modern treatment in patients of malignant plevral effusions resistent sistem therapy	Russian Journal of Oncology	К. С. Титов, В. А. Горбунова et al.	0
16	Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial breakdown →	Journal of Clinical Oncology	Jaffer A. Ajani, W. Rodriguez et al.	425
17	Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial breakdown →	The Lancet	Bernard Escudier, A Płużańska et al.	1722
18	B1-06: Multicenter, randomized study of Docetaxel versus Docetaxel plus Oblimersen in patients previously treated for non-small cell lung cancer (NSCLC)	Journal of Thoracic Oncology	Roy S. Herbst, Rafat Ansari et al.	2
19	Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study	Annals of Oncology	Carmelo Pozzo, C. Barone et al.	126
20	Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases	Annals of Oncology	Jean‐Jacques Body, Ingo Diel et al.	296

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact